NAC Dosage Ranges
For acetaminophen overdose, use a loading dose of 140 mg/kg orally (or 150 mg/kg IV) followed by maintenance doses of 70 mg/kg orally every 4 hours for 17 doses, with the FDA-approved protocol providing specific weight-based dosing tables that should be followed precisely. 1
Acetaminophen Overdose (Primary Indication)
Oral Dosing Protocol
The FDA-approved oral regimen consists of 1:
- Loading dose: 140 mg/kg body weight
- Maintenance dose: 70 mg/kg every 4 hours for 17 additional doses (total 18 doses over 72 hours)
- Preparation: Dilute 20% solution to 5% by adding 3 mL of diluent per 1 mL of NAC (each mL of 20% solution contains 200 mg NAC)
Weight-based dosing examples from FDA label 1:
- 100-109 kg patient: 15 g loading dose (75 mL of 20% solution), then 7.5 g maintenance doses
- 60-69 kg patient: 10 g loading dose (50 mL of 20% solution), then 5 g maintenance doses
- 20-29 kg patient: 4 g loading dose (20 mL of 20% solution), then 2 g maintenance doses
For patients under 20 kg, calculate the exact dose using 140 mg/kg for loading and 70 mg/kg for maintenance 1.
Intravenous Dosing Protocol
The standard IV regimen delivers 300 mg/kg over 20-21 hours 2:
- Traditional 3-bag protocol: 21 hours total
- 2-bag FDA regimen: 20 hours total
- SNAP protocol: 300 mg/kg over 12 hours (can be extended if stopping criteria not met) 2
Critical timing consideration: Efficacy is time-dependent. Hepatotoxicity rates with NAC treatment are 2.9% when started <8 hours, 6.1% when <10 hours, but rise to 26.4% when >10 hours post-ingestion 3. The guidelines strongly recommend administering NAC as early as feasible to maximize benefit 3.
Special Populations in Overdose
Patients >100 kg: Use actual body weight-based dosing rather than capping at 100 kg. Studies show clinicians successfully use 140 mg/kg oral (range 127-143 mg/kg) and 150 mg/kg IV (range 108-168 mg/kg) in patients up to 160 kg, with adverse events being common but not serious 4.
Hepatic failure from acetaminophen: Continue NAC even in established hepatic failure, as it reduces mortality by 28% (80% vs 52%), decreases cerebral edema, and reduces need for inotropic support 3.
Chronic Respiratory Diseases
COPD and Chronic Bronchitis
Standard dose: 600 mg twice daily (1,200 mg/day total) is the optimal dose for preventing exacerbations 5, 6.
- Low-dose NAC (≤600 mg/day) reduces acute exacerbations (RR 0.84, P=0.02) 6
- High-dose NAC (>600 mg/day) shows no statistically significant additional benefit (RR 0.88, P=0.19) 6
- During acute exacerbations: Lower doses may aid recovery, though specific dosing not well-defined 5
Bronchiectasis
Optimal dose: 1,200 mg/day is significantly more effective than 600 mg/day 7.
The 1,200 mg/day regimen demonstrates:
- 48.6% reduction in exacerbations (P=0.01)
- 29.9% reduction in hospitalizations (P=0.038)
- 54.1% reduction in total exacerbation rates (P=0.002)
- 24.3% decrease in patients with >20 cc/day sputum volume (P=0.001) 7
Cystic Fibrosis
Typical dosing: 600-3,000 mg/day has been studied, with safety profiles similar across this range 8. NAC improves lung function, mucociliary clearance, and disrupts biofilms 5.
Pediatric Respiratory Diseases
Acute conditions: 20 mg/kg/day (oral) 9 Chronic conditions: 200 mg three times daily (600 mg/day total) for children >9 years 9
Critical caveat: Most pediatric data comes from children >9 years. For younger children (2-9 years), weight-based dosing is recommended due to significant weight variations, though optimal dosing lacks robust evidence 9.
Nebulized/Inhaled NAC (Mucolytic Use)
From FDA labeling 1:
- Face mask/mouthpiece/tracheostomy: 3-5 mL of 20% solution, 3-4 times daily (can use 1-10 mL every 2-6 hours)
- Direct instillation: 1-2 mL every 1-4 hours
- Tent/Croupette: Volume sufficient to maintain heavy mist (may require up to 300 mL per treatment)
Safety Profile Across Dosing Ranges
High-dose safety: NAC has been studied at doses up to 3,000 mg/day in chronic respiratory diseases with a safety profile similar to standard 600 mg/day dosing 8. Gastrointestinal symptoms are the most common adverse effects but occur no more frequently than in control groups 8.
Anaphylactoid reactions: More common with IV administration in overdose settings, but newer simplified protocols (SNAP, 2-bag regimen) have reduced these rates 2.